What Montana Cancer Consortium does

Montana Cancer Consortium (MCC) is an independent nonprofit organization headquartered in Billings, Montana, founded in 1977 to bring National Cancer Institute (NCI)-sponsored clinical trials to community oncology settings across the rural Mountain West. The organization operates as a Community Oncology Research Program (NCORP) member under the National Cancer Institute, coordinating more than 120 active treatment, cancer control, care delivery, and prevention trials across 13+ disease categories including brain, breast, gastrointestinal, genitourinary, gynecologic, head and neck, leukemia, lung, lymphoma, myeloma, sarcoma, skin, thoracic, and neuroendocrine.

MCC distributes trial access through a network of 16 member cancer centers and hospitals across Montana, Idaho, Wyoming, and Alaska, with dedicated Lead Investigators covering the four National Clinical Trials Network (NCTN) groups: Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network. The organization provides a Member Portal offering exclusive clinical trial documents, open protocols, pharmacy resources, reconsent forms, and training materials to affiliated investigators and research coordinators. Its technology profile is non-proprietary; MCC operates as a coordination and regulatory layer rather than a software or data platform.

MCC's revenue model is grant-based, primarily funded through NCI NCORP sponsorship for clinical trial conduct, supplemented by member institutional contributions. The organization does not disclose pricing or commercial pricing models and offers a public donation channel. Governance is distributed across a Director (Amanda Dinsdale), a Contact Principal Investigator (John Schallenkamp, MD), and per-NCTN-group Lead Investigators. The organization has no disclosed venture capital or private equity backing, no parent entity, and no M&A history in the source material.

Name

Montana Cancer Consortium

Legal name

Montana Cancer Consortium

Website

https://mtcancer.org

Company type

Private

Founded year

1977

Operating status

Operating

Headcount range

11–50 employees

Short description

Montana Cancer Consortium is a Billings-based independent nonprofit that coordinates National Cancer Institute-sponsored clinical trials across 16 member cancer centers in Montana, Idaho, Wyoming, and Alaska.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Voluntary Health Organizations (813212)

SIC

Services-Health Services (8000), Services-Membership Organizations (8600)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Oncology clinical trials
• Cancer research coordination
• Community oncology research
• NCI-sponsored trials
• Cancer care delivery

Headquarters

HQ city

Billings

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Revenue model

1. NCI-Sponsored Research Funding: As an NCI Community Oncology Research Program (NCORP) member, MCC receives funding from the National Cancer Institute to conduct NCI-sponsored clinical trials. This funding supports treatment, prevention, control, and care delivery research.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Montana Cancer Consortium is an independent nonprofit clinical research organization that facilitates patient access to more than 120 NCI-sponsored cancer clinical trials across Montana, Idaho, and Wyoming. Its core offering is the coordination, administration, and conduct of treatment, cancer control, care delivery, and prevention clinical trials through a network of 16 member cancer centers and board-certified oncology specialists.

Product overview

Montana Cancer Consortium operates as a single unified clinical research platform focused on NCI-sponsored cancer clinical trials. The organization offers a portfolio of more than 120 treatment, cancer control, care delivery, and prevention trials accessible through its member portal. These trials are organized into disease-specific portfolios (Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lymphoma, Myeloma, Sarcoma, Skin, Thoracic, and Endocrine Neuroendocrine) and supported by MCC Protocols including pharmacy and training resources. The member portal provides secure access to exclusive trial documents and protocols for affiliated researchers and healthcare providers across Montana, Idaho, and Wyoming.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trials Research Over 120 National Cancer Institute (NCI) sponsored clinical trials covering treatment, cancer control, care delivery, and prevention studies across multiple cancer types, made available to cancer patients in Montana, Idaho, and Wyoming through member institutions.
• Disease Portfolios Structured disease-specific collections of MCC clinical trials organized by cancer type, including Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lymphoma, Multiple Myeloma, Sarcoma, Skin, Thoracic/Lung, Neuroendocrine, Thyroid, and other categories.
• Member Portal Secure member access platform providing exclusive cancer trial documents, protocols, and resources for affiliated researchers, clinical research staff, and healthcare providers participating in the MCC network.
• Open MCC Protocols Open MCC Protocols including spreadsheets of available protocols, pharmacy resources, reconsent forms, and training materials supplied for clinical research staff working at member sites.

Quantifiable outcome

• 120+ clinical trials available across treatment, prevention, control, and care delivery research

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

14 partnerships are on record, tiered core.

• National Cancer Institute (NCI)coreStrategic or Co-development PartnerMCC operates as an NCI Community Oncology Research Program (NCORP) member, receiving NCI sponsorship for clinical trials. This affiliation provides access to NCI-sponsored research protocols, funding, and network coordination through the National Clinical Trials Network (NCTN).
• Alliance for Clinical Trials in OncologycoreStrategic or Co-development PartnerNCTN group providing clinical trial protocols and research coordination. MCC investigators participate in Alliance trials under the Alliance Lead Investigator.
• ECOG-ACRIN Cancer Research GroupcoreStrategic or Co-development PartnerNCTN group focused on cancer control, prevention, and diagnostic imaging research. MCC participates through the ECOG-ACRIN Lead Investigator.
• NRG OncologycoreStrategic or Co-development PartnerNCTN group formed from merger of NSABP, RTOG, and GOG. MCC participates through the NRG Lead Investigator.
• SWOG Cancer Research NetworkcoreStrategic or Co-development PartnerNCTN group focused on cancer treatment, control, and prevention trials. MCC participates through the SWOG Lead Investigator.
• Billings CliniccoreStrategic or Co-development PartnerMember cancer center in Billings, MT providing clinical trial site and investigator support. Christopher Goulet, MD serves as Alliance Lead Investigator.
• Kootenai Clinic Cancer ServicescoreStrategic or Co-development PartnerMember cancer center with locations in Coeur d'Alene, Post Falls, and Sand Point, Idaho. Jeffrey Allen, MD serves as Principal Investigator.
• Bozeman HealthcoreStrategic or Co-development PartnerMember cancer center in Bozeman, MT. Justin Thomas, MD serves as ECOG-ACRIN Lead Investigator.
• Cheyenne Regional Medical CentercoreStrategic or Co-development PartnerMember cancer center in Cheyenne, WY. John Schallenkamp, MD serves as Contact Principal Investigator.
• Benefis Health SystemcoreStrategic or Co-development PartnerMember health system with cancer centers in Great Falls and Helena, MT.
• Logan HealthcoreStrategic or Co-development PartnerMember cancer center in Kalispell, MT providing oncology research services.
• Community Medical CentercoreStrategic or Co-development PartnerMember cancer center in Missoula, MT. Michelle Proper, MD serves as NRG Lead Investigator.
• Great Falls CliniccoreStrategic or Co-development PartnerMember cancer center in Great Falls, MT providing oncology research services.
• Community Hospital of AnacondacoreStrategic or Co-development PartnerMember hospital in Anaconda, MT. James Hueftle, MD serves as SWOG Lead Investigator.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• SWOG Cancer Research Network: One of the four NCTN groups MCC participates in as an affiliated Lead Investigator site. SWOG runs cancer treatment, control, and prevention trials that MCC helps execute, making it a direct operating peer in community oncology research delivery.
• NRG Oncology: One of the four NCTN groups MCC participates in, formed from the merger of NSABP, RTOG, and GOG. MCC executes NRG protocols via its NRG Lead Investigator, making it a direct operating peer in cooperative group oncology research.
• Ochsner Health NCORP: A multi-state community oncology research program and NCORP awardee operating in the Gulf South. Operates the same NCORP model as MCC — bringing NCI-sponsored trials into community settings — making it a direct structural peer.
• Alliance for Clinical Trials in Oncology: One of the four NCTN groups MCC participates in through its Alliance Lead Investigator. Alliance conducts adult cancer clinical trials across the same network structure as MCC, making it a directly comparable peer in cooperative group research delivery.
• Carle Cancer Center NCORP: An Illinois-based NCORP community site that delivers NCI-sponsored oncology trials in community settings. Operates the same NCORP-funded model as MCC and competes for community trial execution across the Midwest.
• ECOG-ACRIN Cancer Research Group: One of the four NCTN groups MCC participates in, focused on cancer control, prevention, and diagnostic imaging research. MCC runs ECOG-ACRIN trials through its designated Lead Investigator, making it a directly comparable protocol and operations peer.

Broad incumbents

• Mayo Clinic Comprehensive Cancer Center: One of the largest NCI-designated Comprehensive Cancer Centers in the US, with deep oncology research operations and a national referral base. While its primary focus is academic oncology, it competes with MCC for high-acuity Mountain West patients and trial enrollees.
• The US Oncology Network: One of the largest community oncology networks in the US, supporting community-based cancer care and clinical research across many states. Operates at significantly larger scale than MCC and competes for community oncology trial execution and patient referrals nationally.
• Huntsman Cancer Institute: An NCI-designated Comprehensive Cancer Center at the University of Utah that runs a broader portfolio of cancer research, including Mountain West community outreach. While it serves a wider mission than MCC, it is a regional incumbent in oncology research and can absorb community trial referrals that might otherwise flow to MCC.
• University of Colorado Cancer Center: NCI-designated Comprehensive Cancer Center serving the broader Mountain West region. Operates a wider portfolio of oncology research and clinical trials than MCC and is a regional incumbent whose catchment overlaps with southern Wyoming and parts of MCC's service area.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/MTCancerTrials
• Facebookfacebook.com/MontanaCancerConsortium
• LinkedInlinkedin.com/company/montana-cancer-consortium

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Montana Cancer Consortium